![]()
Value For Patients
- Fast, out-patient procedure with short recovery at home
- Non-invasive therapy: no surgery, no scars, no ionizing radiation
Disclaimer: SONALLEVE®MR-HIFU is approved for commercial sale in the European Union (EU) for ablation of uterine fibroids or adenomyotic tissue, bone pain palliation associated with bone metastasis, treatment of osteoid osteoma, and management of benign desmoid tumors.
In the United States, SONALLEVE®MR-HIFU is approved by the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE) for the treatment of osteoid osteoma only.
The availability of SONALLEVE® may vary by country and is subject to local regulatory approvals. Not all indications described may be approved in every market.
For detailed information regarding the regulatory status of SONALLEVE® in your region, please contact [email protected].
106731C
CAUTION: Products shown may not be approved for sale in all jurisdictions. Rx only device.
Contact us at [email protected] for more information regarding the regulatory status of the device.